Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

NCT05524103 is registered in ClinicalTrials.gov with AlaMab Therapeutics (Shanghai) Inc. as lead sponsor.

NCT NCT05524103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury
Lead sponsor
AlaMab Therapeutics (Shanghai) Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 15, 2022
Completion date
February 8, 2025
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury